HTLV-II–Mediated Protection From Apoptosis of TF1 Cells After Treatment of the Virus With Anti-HLA Class I (B9.12.1) or Anti-HLA Class II (Tu35, D1.12) Antibodies
| TF-1 Cell Condition . | Time (days) . | ||
|---|---|---|---|
| 1 . | 4 . | 8 . | |
| +IL3 | 0* | 5 | 3 |
| −IL3 | ND | 43 | 50 |
| −IL3 + HTLV-IIMoC344 | ND | 5 | 16 |
| −IL3 + [HTLV-IIMoC344 + D1.12] | ND | 1 | 11 |
| −IL3 + [HTLV-IIMoC344 + Tu35] | ND | 5 | 13 |
| −IL3 + [HTLV-IIMoC344 + B9.12.1] | ND | 5 | 19 |
| −IL3 + HTLV-IIMoBJAB | ND | 36 | 67 |
| −IL3 + [HTLV-IIMoBJAB + D1.12] | ND | 3 | 12 |
| −IL3 + [HTLV-IIMoBJAB + Tu35] | ND | 6 | 10 |
| −IL3 + [HTLV-IIMoBJAB + B9.12.1] | ND | 28 | 58 |
| TF-1 Cell Condition . | Time (days) . | ||
|---|---|---|---|
| 1 . | 4 . | 8 . | |
| +IL3 | 0* | 5 | 3 |
| −IL3 | ND | 43 | 50 |
| −IL3 + HTLV-IIMoC344 | ND | 5 | 16 |
| −IL3 + [HTLV-IIMoC344 + D1.12] | ND | 1 | 11 |
| −IL3 + [HTLV-IIMoC344 + Tu35] | ND | 5 | 13 |
| −IL3 + [HTLV-IIMoC344 + B9.12.1] | ND | 5 | 19 |
| −IL3 + HTLV-IIMoBJAB | ND | 36 | 67 |
| −IL3 + [HTLV-IIMoBJAB + D1.12] | ND | 3 | 12 |
| −IL3 + [HTLV-IIMoBJAB + Tu35] | ND | 6 | 10 |
| −IL3 + [HTLV-IIMoBJAB + B9.12.1] | ND | 28 | 58 |
C344-derived or BJAB-derived virions were incubated with saturating concentration of each antibody, for 2 hours at 4°C and 2 hours at 37°C before contact with IL-3–deprived TF-1 cells.
Abbreviation: ND, not determined.
Values are expressed as the mean percentage of apoptotic cells at the various times analyzed (see Table 1 for procedures) from four independent experiments per condition.